| Original language | English (US) |
|---|---|
| Pages (from-to) | 754-756 |
| Number of pages | 3 |
| Journal | American Journal of Kidney Diseases |
| Volume | 79 |
| Issue number | 5 |
| DOIs | |
| State | Published - May 2022 |
ASJC Scopus subject areas
- Nephrology
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
End Points for Clinical Trials in Hyperoxaluria : Case Study of Patient-Focused Drug Development in a Rare Disease. / Lieske, John C.; Malley, Meaghan A.; West, Melissa et al.
In: American Journal of Kidney Diseases, Vol. 79, No. 5, 05.2022, p. 754-756.Research output: Contribution to journal › Editorial › peer-review
}
TY - JOUR
T1 - End Points for Clinical Trials in Hyperoxaluria
T2 - Case Study of Patient-Focused Drug Development in a Rare Disease
AU - Lieske, John C.
AU - Malley, Meaghan A.
AU - West, Melissa
AU - Hollander, Kim
AU - Milliner, Dawn S.
N1 - Funding Information: Dr Milliner has received consulting fees from OxThera, Dicerna, Allena, Synlogic, and Alnylam, and grant funding from OxThera and Alnylam. Dr Lieske has received consulting fees from Alnylam, OxThera, Dicerna, Synlogic, Orfan-Bridgebio, and Novobiome, and grant support from Alnylam, Allena, Retrophin, OxThera, and Dicerna. Meaghan Malley and Melissa West are employed by the ASN. Kim Hollander is Executive Director of the OHF. Funding Information: The authors were partially supported by the Rare Kidney Stone Consortium (RKSC; U54DK83908), which is part of Rare Diseases Clinical Research Network (RDCRN), an initiative of the Office of Rare Diseases Research (ORDR), National Center for Advancing Translational Sciences (NCATS), R21TR003174, and the Mayo Foundation. The Patient Focussed Drug Development meeting was funded by the OHF. The KHI is funded by the ASN and is a public-private partnership between the ASN, the FDA, and over 100 member companies and organizations.
PY - 2022/5
Y1 - 2022/5
UR - http://www.scopus.com/inward/record.url?scp=85123620621&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85123620621&partnerID=8YFLogxK
U2 - 10.1053/j.ajkd.2021.09.005
DO - 10.1053/j.ajkd.2021.09.005
M3 - Editorial
C2 - 34634431
AN - SCOPUS:85123620621
SN - 0272-6386
VL - 79
SP - 754
EP - 756
JO - American Journal of Kidney Diseases
JF - American Journal of Kidney Diseases
IS - 5
ER -